StreetInsider.com News Articles

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

UPDATE - LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 19:45:00 -0400

UPDATE this press release has been updated to remove a duplicate table.

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs

Form 10-Q LifeMD, Inc. For: Jun 30

Wed, 05 Aug 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260805/26875487.html

Form 10-Q LifeMD, Inc. For: Jun 30

Wed, 05 Aug 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260805/26875487.html

Form 10-Q LifeMD, Inc. For: Jun 30

Wed, 05 Aug 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260805/26875487.html

LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 16:11:00 -0400

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs and the continued scaling of the Company’s in-house pharmacy.
Weight Management Program subscribers grew to

LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 16:11:00 -0400

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs and the continued scaling of the Company’s in-house pharmacy.
Weight Management Program subscribers grew to

LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 16:11:00 -0400

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs and the continued scaling of the Company’s in-house pharmacy.
Weight Management Program subscribers grew to

LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 16:11:00 -0400

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs and the continued scaling of the Company’s in-house pharmacy.
Weight Management Program subscribers grew to

LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 16:11:00 -0400

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs and the continued scaling of the Company’s in-house pharmacy.
Weight Management Program subscribers grew to

LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 16:11:00 -0400

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs and the continued scaling of the Company’s in-house pharmacy.
Weight Management Program subscribers grew to

LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 16:11:00 -0400

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs and the continued scaling of the Company’s in-house pharmacy.
Weight Management Program subscribers grew to

LifeMD Reports Second Quarter 2026 Results

Wed, 05 Aug 2026 16:11:00 -0400

Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially.
Approximately 95% of all new weight management patients now begin treatment with branded GLP-1 therapies; with the guidance provided today, the Company believes it is effectively at the end of its transition away from compounded GLP-1 medications.
Gross margin expanded approximately 280 basis points versus the second quarter of 2025 to approximately 89%, reflecting lower shipping and fulfillment costs and the continued scaling of the Company’s in-house pharmacy.
Weight Management Program subscribers grew to